A new report from the Government Accountability Office finds a slowdown in new drugs coming to market. One culprit? Abusive patent practices, says the GAO.
Big Pharma may be spending big money on drug research, but it’s not getting big breakthroughs. That’s the assessment of a report released in December by the Government Accountability Office that blames patents, among other things, for why innovative new drugs aren’t coming to market.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
For questions call 1-877-256-2472 or contact us at [email protected]